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Summary
Abstract
Background—NLRP3 inflammasome-directed pyroptotic cell death drives ineffective 
haemopoiesis in myelodysplastic syndromes. During inflammasome assembly, the apoptosis-
associated speck-like protein containing a CARD (PYCARD, commonly known as ASC) adaptor 
protein polymerises into large, filamentous clusters termed ASC specks that are released upon 
cytolysis. Specks are resistant to proteolytic degradation because of their prion-like structure, and 
therefore might serve as a biomarker for pyroptotic cell death in myelodysplastic syndromes.
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Methods—This observational cohort study was done at the H Lee Moffitt Cancer Center (Tampa, 
FL, USA). Patients with myelodysplastic syndromes, healthy controls, and patients with non-
myelodysplastic syndrome haematological cancers or type 2 diabetes were recruited. We used 
confocal and electron microscopy to visualise, and flow cytometry to quantify, ASC specks in 
peripheral blood and bone marrow plasma samples. Speck percentages were compared by t test or 
ANOVA, correlations were assessed by Spearman’s rank correlation coefficient, and biomarker 
efficiency was assessed by receiver operating characteristics and area under the curve (AUC) 
analysis.
Findings—Between Jan 1, 2005, and Jan 12, 2017, we obtained samples from 177 patients with 
myelodysplastic syndromes and 29 healthy controls for the discovery cohort, and 113 patients with 
myelodysplastic syndromes and 31 healthy controls for the validation cohort. We also obtained 
samples from 22 patients with del(5q) myelodysplastic syndromes, 230 patients with non-
myelodysplastic syndrome haematological cancers and 23 patients with type 2 diabetes. After 
adjustment for glucose concentration, the log10-transformed mean percentage of peripheral blood 
plasma-derived ASC specks was significantly higher in the 177 patients with myelodysplastic 
syndromes versus the 29 age-matched, healthy donors (−0.41 [SD 0.49] vs −0.67 [0.59], p=0.034). 
The percentages of ASC specks in samples from patients with myelodysplastic syndromes were 
significantly greater than those in samples from individuals with every other haematological 
cancer studied (all p<0.05) except myelofibrosis (p=0.19). The findings were confirmed in the 
independent validation cohort (p<0.0001). Peripheral blood plasma danger-associated molecular 
pattern protein S100-A8 and protein S100-A9 concentrations from 144 patients with 
myelodysplastic syndromes from the discovery cohort directly correlated with ASC speck 
percentage (r=0.4, p<0.0001 for S100-A8 and r=0.2, p=0.017 for S100-A9). Patients with at least 
two somatic gene mutations had a significantly greater mean percentage of peripheral blood 
plasma ASC specks than patients with one or no mutation (−0.22 [SD 0.63] vs −0.53 [0.44], 
p=0.008). The percentage of plasma ASC specks was a robust marker for pyroptosis in 
myelodysplastic syndromes (AUC=0.888), in which a cutoff of 0.80 maximised sensitivity at 0.84 
(95% CI 0.65–0.91) and specificity at 0.87 (0.58–0.97).
Interpretation—Our results underscore the pathobiological relevance of ASC specks and 
suggest that ASC specks are a sensitive and specific candidate plasma biomarker that provides an 
index of medullary pyroptotic cell death and ineffective haemopoiesis in patients with 
myelodysplastic syndromes.
Introduction
Pyroptosis is mediated by the formation of NLRP3 inflammasome complexes, which 
function as redox-sensitive, cytosolic sensors of danger signals.1 Uponstimulation, NLRP3 
recruits the adaptor protein apoptosis-associated speck-like protein containing a CARD 
(PYCARD, commonly known as ASC), triggering ASC polymerisation to create large, 
cytoplasmic filaments.2 ASC filaments stack to form a cytoplasmic cluster, referred to as 
specks, which are generally described as about 1–3 μm in diameter and are released into the 
extracellular space after pyroptotic cytolysis.2,3 Because oftheir prion-like structure, specks 
are resistant to proteolytic degradation.3 Extracellular ASC specks retain catalytic activity 
with abundant caspase-1 activation sites, fostering inflammasome signal strengthening that 
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augments the inflammatory response.2–4 Pyroptosis occurs after assembly of the 
inflammasome complex comprised of NLRP3 that is bound to caspase-1 via the adaptor 
molecule ASC. Caspase-1 then undergoes autocatalytic cleavage that activates the 
proenzyme that cleaves and generates mature pro-interleukin iβ. Inflammasome activation 
induces cell swelling, pore formation, and caspase-1-dependent pyroptotic cytolysis with 
expulsion of intracellular contents.1–3
The diagnosis of myelodysplastic syndromes can be challenging because, in addition to the 
substantial disease heterogeneity, diagnosis relies on subjective morphological assessment of 
cytological dysplasia and bone marrow aspirates of variable technical quality.5–7 
Furthermore, many haematological conditions can display dysplastic features, including 
overlap syndromes such as chronic myelomonocytic leukaemia and various benign 
conditions.8 Myelodysplastic syndromes are characterised by ineffective haemopoiesis 
arising in part from caspase-1-dependent pyroptotic death of stem and progenitor cells, as 
well as erythroid and myeloid bone marrow cell compartments.9 We previously published a 
study describing the role of pyroptosis in the underlying mechanism ofineffective 
haemopoiesis in patients with myelodysplastic syndromes. To our knowledge, that was the 
first study to implicate this novel form of cell death in the pathobiology ofmyelodysplastic 
syndromes.9 Myelodysplastic syndrome-related somatic gene mutations can trigger NADPH 
oxidase-dependent generation of reactive oxygen species10,11 that leads to NLRP3 
inflammasome formation, resulting in caspase-1 and β-catenin activation, and pyroptosis. 
This process occurs in the context of common myelodysplastic syndrome somatic gene 
mutations of varied functional classes, including U2 small nuclear RNA auxiliary factor 1 
(U2AF1), splicing factor 3b subunit 1 (SF3B1), serine and arginine rich splicing factor 2 
(SRSF2), additional sex combs like 1, transcriptional regulator (ASXL1), and Tet 
methylcytosine dioxygenase 2 (TET2), recognised as splicing, methylation, and transcription 
factor genes.9 On the basis of these investigations showing that NLRP3 inflammasome 
activation directs pyroptotic cell death in myelodysplastic syndrome bone marrow 
progenitors,9 we rationalised that this would generate higher percentages of bone marrow 
and peripheral blood specks in patients with myelodysplastic syndromes than in healthy 
donors and patients with other haematological cancers. ASC specks might be a surrogate 
marker for the magnitude of intramedullary pyroptosis in bone marrow samples from 
patients with myelodysplastic syndromes.9 Furthermore, given their resistance to protease 
degradation, we hypothesised that ASC specks from peripheral blood plasma might also be a 
biologically rational biomarker for the diagnosis and monitoring of ineffective haemopoiesis 
in patients with myelodysplastic syndromes. The main objective of this study was to 
establish whether ASC specks, a measure of pyroptosis, are significantly increased in 
peripheral blood plasma from patients with myelodysplastic syndromes as compared with 
healthy controls and patients with other haematological cancers.
Methods
Study design and participants
This observational cohort study was done at the H Lee Moffitt Cancer Center (Tampa, FL, 
USA). Patients with myelodysplastic syndromes, non-myelodysplastic syndrome 
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haematological cancers, and type 2 diabetes, and healthy controls were recruited. 
Myelodysplastic syndrome diagnoses were done by morphological assessment according to 
the 2016 revision of the WHO Classification of Myelodysplastic Syndromes.12 Patients with 
myelodysplastic syndromes who had a chromosome 5 deletion (del[5q]) were analysed 
separately from non-del[5q] patients because of differences in disease biology. Inclusion 
criteria for healthy controls were age of at least 60 years and no history of type 2 diabetes or 
cancer. Inclusion criteria for all disorders only required physician diagnosis with no 
exclusion based on treatment status; patients with both diabetes and haematological cancer 
diagnoses were eligible. Patients and healthy donors gave written informed consent for 
participation in the study. The protocol was approved by the Institutional Review Board or 
equivalent regulation board for each institution that provided specimens. All patients except 
for those for the validation cohort were acquired by the H Lee Moffitt Cancer Center.
Procedures
Peripheral blood plasma samples from patients with non-del(5q) myelodysplastic syndromes 
were age matched to samples from healthy controls, patients with del (5q) myelodysplastic 
syndromes, patients with other haematological cancers, or individuals with type 2 diabetes. 
Bone marrow plasma samples were taken from patients with non-del(5q) myelodysplastic 
syndromes. These patients were stratified according to the International Prognostic Scoring 
System. We defined lower-risk patients as those with low or intermediate-1 risk and higher-
risk patients as those with intermediate-2 or high risk.
Microscopy—We compared percentage of ASC specks in bone marrow and peripheral 
blood samples from patients with non-del(5q) myelodysplastic syndromes with those from 
healthy donors and patients with other haematological cancers. We used confocal immune-
fluorescence and electron microscopy to visualise intracellular ASC specks, which are 
distinguished as solitary punctate cytoplasmic ASC aggregates (figure 1; appendix). Slides 
were imaged using a Leica SP8 confocal microscope (Leica Microsystems, Wetzlar, 
Germany). Speck puri-fication was performed as previously described13 and imaged using a 
haemocytometer and the EVOS Autoimager (Thermo Fisher Scientific, Waltham, MA, 
USA) or, after being allowed to dry on a formvar-coated grid, using a Jeol JEM1400 
transmission electron microscope (Jeol USA Inc, Peabody, MA, USA; appendix).
Flow cytometry—To assess the relationship between reported genetic drivers 
ofmyelodysplastic syndromes and inflammasome-derived ASC specks, we analysed the 
glucose-adjusted log10-transformed percentage of ASC specks in peripheral blood plasma in 
all patients and healthy controls. Flow cytometry was performed with modification to 
previously described methods (appendix).3,14 We did not implement a size threshold to 
identify specks that would favour only the largest aggregates. The percentage of ASC specks 
was quantified using a secondary antibody-only tube as the negative control. Data were 
analysed using FloJo software and reported as percentage of positive events or percentage of 
specks. These data were then adjusted for total glucose concentrations and transformed by 
log10 for analysis. We compared matched samples of peripheral blood and bone marrow 
plasma from the patients with myelodysplastic syndromes; and peripheral blood samples 
from patients with non-del(5q) myelodysplastic syndromes versus samples from healthy 
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controls, patients with different haematological cancers, and patients with type 2 diabetes 
(appendix).
ELISA—The danger-associated molecular pattern (DAMP) protein S100-A9 initiates 
NLRP3 inflammasome activation anxptotic death in haemopoietic stem cells and progenitor 
cells in patients with lower-risk myelodysplastic syndromes.9 To confirm the specificity of 
NLRP3 inflammasome-derived ASC specks as a measure of ineffective haemopoiesis, we 
measured protein S100-A8 and protein S100-A9 concentrations by ELISA with CircuLex 
ELISA kits (MBL International Corporation, Woburn, MA, USA) in the peripheral blood 
samples from the patients with non-del(5q) myelodysplastic syndromes only. Peripheral 
blood plasma glucose concentrations were measured using a glucose colorimetric assay kit 
(Cayman Chemical, Ann Arbor, MI, USA).
Sequencing—Gene sequencing was performed in the patients with non-del(5q) 
myelodysplastic syndromes on bone marrow mononuclear cells as previously described15 or 
using a next-generation sequencing-targeted gene panel, which included up to 54 genes with 
a variant allele frequency threshold of 5% and a 500×minimum depth of coverage.
Statistical analysis
The discovery cohort included all patients with non-del(5q) myelodysplastic syndromes for 
whom peripheral blood plasma samples were available in our laboratory. To optimise the 
assay for disease-specific pyroptosis, ASC speck percentage was normalised to plasma 
glucose concentration to adjust for possible confounding effects of hyperglycaemia. 
Hyperglycaemia is a known activator of the NLRP3 inflammasome, and in myelodysplastic 
syndromes, bone marrow plasma glucose concentrations are greatly increased as a result of 
inflammasome-driven insulin resistance.16–18 Therefore, we adjusted for glucose 
concentration to distinguish disease-specific inflamma-some activation.
Paired samples (peripheral blood and bone marrow) were compared using paired t tests. The 
two-sided t test of log10-transformed peripheral blood plasma specks normalised to glucose 
concentration was used to compare patients with myelodysplastic syndromes with healthy 
controls. Wilcoxon signed-rank test was used to compare diseases with fewer than ten 
patients. Correlations between log10-normalised percentage of ASC specks and log10-
normalised protein S100-A8 and protein S100-A9 concentrations were analysed using 
Spearman’s rank correlation coefficient. Biomarker efficiency was analysed using receiver 
operating characteristics (ROC) and areas under the curve (AUC) as effective measures of 
accuracy for myelodysplastic syndromes versus controls, or by k-fold cross-validation when 
comparing patients with myelodysplastic syndromes to those with non-myelodysplastic 
syndrome haematological cancers. To power the validation cohort, a sample of 39 cases 
from the positive group and 39 from the negative group achieved 81% power to detect a 
difference of 0 2 between the AUC under the null hypothesis of 0.65 and an AUC under the 
alternative hypothesis of 0.8 using a one-sided z test at a significance level of 0.05. The ratio 
of the standard deviation of the responses in the negative group to the standard deviation of 
the responses in the positive group was 1.00. Mutation analyses were performed by one-way 
ANOVA or paired group t test. Statistical analyses were done using R, version 3.4.2.
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Role of the funding source
The funders of the study had no role in study design, data collection, analysis, or 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication.
Results
Specimens collected between Jan 1, 2005, and Jan 12, 2017, were used for this study. 
Specimens were from 290 patients with non-del(5q) myelodysplastic syndromes, 60 healthy 
controls, 22 patients with del(5q) myelodysplastic syndromes, 230 patients with non-
myelodysplastic syndrome haematological cancers, and 23 patients with type 2 diabetes 
(table 1; appendix). The discovery cohort consisted of 177 patients with myelodysplastic 
syndromes (mean age 70 years [SD 8.4]; 162 [92%] with lower-risk and 15 [8%] with 
higher-risk disease) and 29 healthy controls with no previous or current cancer or diabetes 
diagnosis (mean age 65 years [5.0]). The validation cohort consisted of 113 patients with 
myelodysplastic syndromes (mean age 72 years [7.2]; 66 [58%] with lower-risk and 47 
[42%] with higher-risk disease) and 31 healthy controls with no previous or current cancer 
or diabetes diagnosis (mean age 74 years [6.0]). Distribution of morphological subtypes 
according to the 2016 revision of the WHO Classification of Myelodysplastic Syndromes12 
included patients with myelodysplastic syndromes with single-lineage dysplasia (SLD), with 
SLD and ringed sideroblasts (SLD-RS), with multilineage dysplasia (MLD), with MLD-RS, 
with excess blasts, patients with unclassified myelodysplastic syndromes, and patients with 
myelodysplastic syndromes not otherwise specified.
Extracellular ASC specks were quantified using flow cytometry in matched peripheral blood 
and bone marrow plasma samples from 38 patients with myelodysplastic syndromes. 
Peripheral blood plasma had a significantly higher mean percentage of specks than bone 
marrow plasma (24.9% [SD 12.4] vs 15.3% [9.7]; p<0.0001; figure 2A). Given the 
accessibility of peripheral blood for diagnostic screening, further investigations should focus 
solely on peripheral blood plasma-derived ASC specks rather than bone marrow plasma 
samples.
The log10-transformed and glucose-adjusted mean percentage of peripheral blood ASC 
specks was significantly greater in peripheral blood samples from patients with non-del(5q) 
myelodysplastic syndromes (−0.36 [SD 0.41], p=0.034), and in those with lower-risk disease 
(−0.33 [0.34], p=0.0075) versus the healthy donors (−0.51 [0.67]; figure 2B). Consistent 
with our previous findings of a higher pyroptotic cell fraction in patients with lower-risk 
myelodysplastic syndromes,9 a higher mean percentage of ASC specks were present in 
lower-risk than in higher-risk myelodysplastic syndrome plasma samples (lower-risk −0.33 
[SD 0–33] vs higher-risk −1.01 [0.55], p<0.0001; figure 2B). We found that the percentage 
of ASC specks was significantly lower in patients with myelodysplastic syndromes with 
isolated del(5q) than in the non-del(5q) patients (with single-lineage dysplasia, multilineage 
dysplasia, excess blasts, or unclassified subtypes), with no discernible differences among 
any of the non-del(5q) subtypes (figure 2C). The mean percentage of ASC specks was 
−1.243 (SD 0.52) in patients with del(5q) myelodysplastic syndromes, −0.506 (0.63) for 
those with myelodysplastic syndromes with excess blasts, −0.437 (0.52) for those with 
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MLD, −0.348 (0.45) for those with SLD, and −0.466 (0.51) for unclassified myelodysplastic 
syndromes (figure 2C).
In the analysis of peripheral blood ASC specks as a diagnostic tool, the glucose-adjusted 
log10 percentage of ASC specks in samples from patients with non-del(5q) myelodysplastic 
syndromes was significantly greater than the percentage of specks from those with del(5q) 
myelodysplastic syndromes and all other haematological cancers we studied (all p<0.05), 
with the exception of myelofibrosis, which was present in only three participants in our 
study (p=0.19; table 2, figure 2B). In peripheral blood samples from patients with type 2 
diabetes, ASC specks were significantly fewer than those from healthy control samples 
(p<0.0001) or samples from patients with non-del(5q) myelodysplastic syndrome 
(p<0.0001).
To validate these findings, we studied samples from the validation cohort of patients with 
non-del(5q) myelodysplastic syndromes and age-matched healthy controls. We confirmed 
that ASC specks were significantly increased in the plasma of patients with myelodysplastic 
syndromes compared with healthy controls (p<0.0001; figure 2D). A ROC-AUC analysis 
was done in the validation and discovery cohorts to assess the specificity and sensitivity of 
ASC specks as a possible pyroptosis-specific biomarker in myelodysplastic syndromes. 
ROC-AUC analysis illustrates the diagnostic accuracy of a two-class prediction of a 
validation cohort using the logistic regression model on the discovery cohort. By ROC-AUC 
analyses, we showed that ASC specks could be considered as a robust biomarker of 
pyroptosis linked to myelodysplastic syndromes (AUC=0.888; figure 3), and was highly 
sensitive for lower-risk myelodysplastic syndromes (AUC=0.951). Our calculations allowed 
us to establish that a log10-transformed, glucose-adjusted percentage of speck threshold of 
0.80 maximised sensitivity (0.84 [95% CI 0.65–0.91]) and specificity (0.87 [0.58–0.97]) for 
all myelodysplastic syndromes, whereas a threshold of 0.761 maximised sensitivity (0.92 
[0.17–0.98]) and specificity (0.94 [0.77–1.0]) for lower-risk myelodysplastic syndromes. 
The threshold output is the point at which both the sensitivity and specificity have the 
greatest values. Adjustment of this threshold can increase either the sensitivity or specificity 
but not both, and therefore, the provided threshold depicts where both are maximised. 
Additionally, in the absence of an independent cohort of non-haematological disorders, we 
did a five-fold cross-validation (k=5), which was repeated 30 times to compare patients with 
myelodysplastic syndromes in the discovery cohort with the control patients who had other 
haematological cancers, yielding a mean AUC of 0.934 (data not shown), showing the 
specificity of this marker with respect to other haematological disorders.
Protein S100-A8 and protein S100-A9 concentrations were measured in 144 peripheral 
blood plasma samples from patients with myelodysplastic syndromes. Protein S100-A8 
(r=0.4, p<0.0001) and protein S100-A9 (r=0.2, p=0.017) concentrations directly correlated 
with glucose-adjusted ASC speck percentages. The concentrations of the two S100 proteins 
were also closely correlated (r=0.5, p<0.0001), consistent with the propensity of these 
proteins to heterodimerise.
In the analysis of the relationship between genetic drivers ofmyelodysplastic syndromes 
(table 3), comparing patients with myelodysplastic syndromes from the validation and 
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discovery cohorts with a specific mutation to all those without any mutation (n=4), ASC 
specks in peripheral blood plasma were significantly increased in patients who have somatic 
mutations involving pre-mRNA splicing genes (p=0·019), methylation genes (p=0·011), 
transcription factor genes (p=0·019), and signalling genes (p=0·029). Further-more, when we 
compared the 78 patients with RNA splicing mutations with the 18 patients without this type 
of mutation, patients with splicing gene mutations had a significantly higher mean 
percentage of plasma ASC specks than participants without (−0·25 [SD 0·61] vs −0·54 
[0·44], p=0·026). Similarly, when we compared the 52 patients with any methylation 
mutation with the 44 patients without, the mean percentage of ASC specks was significantly 
higher in patients with methylation gene mutations (−0·20 [SD 0·69] with these mutations vs 
−0·44 [0·43] without, p=0·039; table 3). The non-founder gene mutation classes (defined as 
non-founder because they are not driver mutations), such as signalling and transcriptional 
genes, did not have significantly different percentages of ASC specks from the other classes 
(table 3). Furthermore, irrespective of mutation class, patients with at least two mutations 
had a significantly greater percentage of peripheral blood plasma ASC specks than patients 
with one or no mutation (−0·22 [SD 0·63] vs −0·53 [0·44], p=0.008; table 3). However, in 
patients with more than two total mutations, additional somatic gene mutations did not have 
an additive effect (p=0.207 for total number of mutations vs percentage of ASC specks; 
figure 4).
Discussion
Collectively, our results indicate that NLRP3 inflammasome-derived ASC specks are highly 
specific for pyroptosis associated with myelodysplastic syndromes. We also highlight here 
the relationship between the presence of myelodysplastic syndrome-related somatic gene 
mutations and peripheral blood plasma ASC speck percentages, which lends further support 
to the relevance of this candidate biomarker as a plausible index of pyroptosis in 
myelodysplastic syndromes.
Because of their prion-like structure, ASC specks are resistant to proteolytic degradation, 
and therefore persist in the environment long after cell death.3,4 Indeed, experiments in 
reporter mice—including a heterozygous mouse model bearing insertion of a green 
fluorescent protein transgene into lysosomes and in wild-type mice3—have shown that 
specks can remain in tissues for up to 96 h after ear injection of fluorescent ASC specks, 
indicating that inflammasome-initiated pyroptosis might have long-lasting effects on 
adjacent stromal cells.3 This might impair stromal support for normal haemopoiesis in 
patients with myelodysplastic syndromes, which is being investigated.3,4 Extracellular ASC 
specks can be engulfed by resident macrophages and visualised in phago-lysosomal 
compartments.3 This observation might explain the lower percentages of ASC specks in 
bone marrow versus peripheral blood plasma noted in our study, although a direct analysis of 
ASC speck phagocytosis by myelodysplastic syndrome macrophages remains to be done.
Because ASC specks are only released during pyroptotic cytolysis,3 they can function as a 
surrogate marker of the magnitude of pyroptosis in bone marrow haemopoietic precursors. 
Using an optimised flow cytometry assay, we showed that the percentage of peripheral blood 
plasma ASC specks was significantly increased in patients with myelodysplastic syndromes 
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compared with an age-matched, healthy control population, in both our discovery and 
validation cohorts. We hypothesised that ASC specks might be more common in peripheral 
blood than bone marrow plasma because the specks can be engulfed by resident 
macrophages in the bone marrow, and we did find a higher percentage of specks in 
peripheral blood samples relative to the bone marrow samples. We observed a greater 
percentage of specks in patients with lower-risk myelodysplastic syndromes than in those 
with higher-risk myelodysplastic syndromes, consistent with a higher pyroptotic cell fraction 
in patients with lower-risk disease. Decreased pyroptosis in patients with higher-risk 
myelodysplastic syndromes might be attributed to decreased S100-A9 concentrations and 
bone marrow myeloid-derived suppressor cells, as well as increased survival signals in 
people with higher-risk myelodysplastic syndromes, but this remains to be shown. However, 
we did not observe differences in ASC speck percentages between patients with different 
WHO subtype classifications except del(5q) myelodysplastic syndromes, which might be 
attributable to the low number of participants with each subtype. As expected, we observed 
decreased ASC speck percentages in peripheral blood from patients with type 2 diabetes as 
compared with individuals with myelodysplastic syndromes, because of the low levels of 
pyroptotic execution despite inflammasome activation. Notably, patients with type 2 diabetes 
also had decreased speck percentages as compared with the healthy control cohort, possibly 
because some of the participants with type 2 diabetes might have received active glycaemia 
control with hypoglycaemic drugs or insulin. The results from the 5-fold crossvalidation 
indicated that the percentage of specks had potential use as a pyroptosis marker in 
myelodysplastic syndromes versus other haematological cancers, showing the specificity of 
ASC specks in samples from patients with myelodysplastic syndrome as compared with 
other haematological cancers. Furthermore, as concentrations of the DAMPs S100-A8 and 
S100-A9 have been shown to correlate directly with the extent of pyroptotic death,9 we also 
showed a correlation between percentage of ASC specks and S100-A8 and S100-A9 
concentrations in plasma. Our results underscore the biological relevance of peripheral blood 
plasma ASC specks as a surrogate marker for the index of pyroptosis induced by S100-A8 
and S100-A9 in peripheral blood plasma. This analysis, as well as thorough analysis of 
common myelodysplastic syndrome somatic gene mutations linked to pyroptosis, further 
support the possibility of using measurement of ASC specks as a biomarker of pyroptosis in 
myelodysplastic syndromes. Our results showed that the percentage of ASC specks in 
patients with somatic gene mutations was significantly increased compared with patients 
who had no gene mutations. Percentage of peripheral blood plasma ASC specks was 
significantly greater in patients who had at least two somatic gene mutations than in patients 
with one or no mutation, although percentages did not increase significantly beyond three 
mutations, which might reflect the smaller sample size of these groups or the class of 
passenger gene mutations. Because transcriptional mutations and signalling mutations are 
not driver mutations, and are therefore referred to as non-founder gene mutations, it seems 
logical that they were not associated with a significant difference in plasma ASC speck 
percentages, perhaps also reflecting the pro-survival effect of these classes of somatic gene 
mutations. However, studies with a larger sample size are needed to assess the relationship 
between specific gene mutations or mutation classes and the extent of pyroptosis.
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An assay for cell pyroptosis in myelodysplastic syndromes that is independent of cell 
morphology could be invaluable for diagnosis. Peripheral blood plasma-derived ASC specks 
might serve as an index of pyroptosis and could be the first biomarker for pyroptosis 
associated with myelodysplastic syndromes that offers a high degree of specificity and 
sensitivity. Newly developed assays such as an ASC ELISA might be better at quantifying 
ASC specks than the flow cytometry assay used in our study, and might offer greater clinical 
utility. Immunofluorescence detection of cytoplasmic specks in bone marrow precursors 
could be an alternative approach for validation of the diagnosis of pyroptosis associated with 
myelodysplastic syndromes in patients presenting with subtle features of cytological 
dysplasia. The results from our study suggest that the detection of ASC specks might be a 
biologically rational peripheral blood biomarker for pyroptosis associated with myelo-
dysplastic syndromes, and could also serve as an index of intramedullary bone marrow 
pyroptosis. Inflammasome inhibition is an attractive strategy for the treatment of patients 
with myelodysplastic syndromes, which has been shown in vitro to restore haemopoiesis,9 
and the diagnostic technique we have identified might help assess responses to therapy. 
Limitations of this study include the overlap in ASC speck percentage values we noted 
among different cancers, which warrants further investigation. Furthermore, it must be noted 
that the use of other biomarkers in combination with the detection of ASC specks is likely to 
improve the specificity of detection of pyroptosis, and this merits further attention. 
Alternative assays to flow cytometry are likely to improve quantitative and accurate 
assessment of ASC specks. Despite these limitations, this study emphasises the potential use 
of detection of ASC specks as a candidate biomarker ofcell death and a complementary 
assessment tool that might facilitate diagnosis of myelodysplastic syndromes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Evidence before this study
On June 15, 2018, we searched PubMed for publications on ASC specks in 
myelodysplastic syndromes, using the search terms “ASC”, “inflammasome”, and 
“MDS”, with no language or publication date restrictions. The only relevant study was 
our previous study, which identified NLRP3 inflammasome-directed pyroptotic cell death 
as a driver of ineffective haemopoiesis in patients with myelodysplastic syndromes, and 
described pyroptosis in the context of non-myelodysplastic syndrome haematological 
cancers. During inflammasome assembly the apoptosis-associated speck-like protein 
containing a CARD (ASC) adaptor protein polymerises into large, filamentous clusters 
termed ASC specks that are released during cytolysis and are resistant to proteolytic 
degradation. Because specks are readily quantified by flow cytometry and measured 
independently of cell morphology, we hypothesised that ASC specks might serve as a 
candidate biomarker associated with pyroptotic cell death in myelodysplastic syndromes, 
which might provide an index of ineffective haemopoiesis and so be used in the diagnosis 
of these cancers.
Added value of this study
By showing the use of ASC specks as a surrogate marker of pyroptosis with specificity 
for myelodysplastic syndromes, our findings suggest that the detection of ASC specks in 
peripheral blood from patients with myelodysplastic syndromes is a candidate biomarker 
for pyroptosis. We also hypothesise that ASC specks could be used as an index of 
intramedullary bone marrow pyroptosis, which might be used in monitoring responses to 
therapy. This hypothesis merits further investigation.
Implications of all the available evidence
These data identify a potential diagnostic companion that distinguishes patients with 
myelodysplastic syndromes from those with other bone marrow cancers. ASC speck 
quantification has potential as a surrogate for pyroptosis that might be applied to assess 
therapeutic responses.
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Figure 1: Visualisation of ASC specks in patients with myelodysplastic syndromes
Representative confocal microscopy micrographs of ASC specks in bone marrow 
mononuclear cells from three patients with myelodysplastic syndromes from the discovery 
cohort. (A) DAPI nuclear staining. (B) Anti-ASC antibody staining. (C) Merged DAPI and 
anti-ASC image (A–C × 2100 magnification). (D and E) Digitally enlarged images of parts 
of C to highlight specks (white arrows). (F) Surface rendering of E. (G) Purified GFP-ASC 
specks from lipopolysaccharide-stimulated or nigericin-stimulated THP-1-GFP-ASC cell 
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lines. (H) Transmission electron microscopy image of GFP-ASC specks isolated from 
stimulated THP-1 cells (× 15 000 magnification).
ASC=apoptosis-associated speck-like protein containing a CARD. GFP=green fluorescent 
protein
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Figure 2: Quantification of ASC specks in bone marrow and peripheral blood from patients with 
myelodysplastic syndromes relative to patients with other haematological cancers, type 2 
diabetes, or healthy donors
ASC=apoptosis-associated speck-like protein containing a CARD. MDS=myelodysplastic 
syndromes. del(5q)=chromosome 5 deletion. ALL=acute lymphocytic leukaemia. 
CLL=chronic lymphocytic leukaemia. CML=chronic myelogenous leukaemia. 
CMML=chronic myelomonocytic leukaemia. AML=acute myeloid leukaemia. LGL=large 
granular lymphocytic leukaemia. SLD=single-lineage dysplasia. MLD=multilineage 
dysplasia. EB=excess blasts. Boxes show median (centre line) and IQR (outer lines) and 
whiskers show SD. (A) Glucose-adjusted percentage of ASC specks in bone marrow and 
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peripheral blood plasma, and difference between peripheral blood and bone marrow in 
samples from patients with myelodysplastic syndromes in the discovery cohort, quantified 
by flow cytometry. (B) Glucose-adjusted log10-transformed percentage of ASC specks in 
peripheral blood plasma from healthy controls and patients with myelodysplastic syndromes 
in the discovery cohort, as well as patients with non-myelodysplastic syndrome 
haematological cancers and type 2 diabetes, quantified by flow cytometry. (C) Glucose-
adjusted log10-transformed percentage of ASC specks quantified by flow cytometry in 
patients with different subtypes of myelodysplastic syndromes from the discovery cohort 
and patients with del(5q) mutation, as categorised by 2016 WHO guidelines. (D) Glucose-
adjusted log10-transformed percentage of ASC specks quantified by flow cytometry in 
peripheral blood plasma samples from patients with myelodysplastic syndromes versus 
healthy controls in the validation cohort.
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Figure 3: Sensitivity and specificity of ASC specks in peripheral blood plasma from patients with 
myelodysplastic syndromes
Receiver operating characteristic AUC analysis of glucose-adjusted log10-normalised ASC 
speck percentage in patients with lower-risk, higher-risk, or any myelodysplastic syndromes 
from the discovery and validation cohorts.
ASC=apoptosis-associated speck-like protein containing a CARD.
MDS=myelodysplastic syndromes. AUC=area under the curve.
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Figure 4: Percentage of peripheral blood plasma ASC specks from patients with myelodysplastic 
syndromes according to number of somatic gene mutations
Boxes show median (centre line) and IQR (outer lines) and whiskers show SD.
Data are from the discovery and validation cohorts (n=96).
ASC=apoptosis-associated speck-like protein containing a CARD.
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Table 1:
Baseline cohort characteristics











Mean age (SD), years   70 (8.4) 65 (5–0) 72 (7–2) 74 (6.0)
Sex
 Men 100 (56%)   0 61 (54%) 4 (13%)
 Women   43 (24%) 29 (100%) 23 (20%) 27 (87%)
 Unknown   34 (19%)   0 29 (26%)   0
Risk category
 Higher-risk   15 (8%) NA 47 (42%) NA
 Lower-risk 162 (92%) NA 66 (58%) NA
WHO myelodysplastic syndromes subtypes
 Single-lineage dysplasia   9 (5%) NA   4 (4%) NA
 Single-lineage dysplasia with ringed sideroblasts 30 (17%) NA 36 (32%) NA
 Multilineage dysplasia 36 (20%) NA 12 (11%) NA
 Multilineage dysplasia with ringed sideroblasts 14 (8%) NA 10 (9%) NA
 Excess blasts 23 (13%) NA 19 (17%) NA
 Not otherwise specified 59 (33%) NA 30 (27%) NA
 Unclassified   6 (3%) NA   2 (2%) NA
NA=not applicable.
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Table 3:
Log10-normalised percentage of peripheral blood plasma ASC specks by classes of somatic gene mutations in 
patients with myelodysplastic syndromes
n Mean (SD) Median (IQR) p value
Splicing gene mutations*
Yes 78 −0·25 (0·61) −0·35
(−0·62 to 0·07)
0·026




Yes 52 −0·20 (0·69) −0·32
(−0·61 to 0·11)
0·039




Yes 37 −0·29 (0·66) −0·34
(−0·62 to 0·08)
0·821




Yes 11 −0·26 (0·66) −0·44
(−0·79 to −0·11)
0·787




Yes 92 −0·28 (0·59) −0·35
(−0·63 to 0·03)
0·024




Yes 68 −0·22 (0·63) −0·32
(−0·60 to −0·11)
0·008
No 28 −0·53 (0·44) −0·50
(−0·85 to −0·31)
  ··
Total number of mutations
0 4 −0·90 (0·32) −0·86
(−1·08 to −0·67)
0·207
1 26 −0·45 (0·43) −0·44
(−0·76 to −0·12)
  ··
2 39 −0·23 (0·54) −0·34
(−0·50 to 0·07)
  ··
3 13 −0·15 (0·60) −0·08
(−0·62 to 0·20)
  ··
4 11 −0·25 (1·02) −0·43
(−0·73 to −0·03)
  ··
5 3 −0·17 (0·30) −0·24
(−0·34 to −0·04)
  ··
ASC=apoptosis-associated speck-like protein containing a CARD.
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*
SF3B1, SRSF2, U2AF, or ZRSR2 mutations.
†
Tet2, IDH, DNMT3A, ASXL1, or EZH2 mutations.
‡
SetBP1, TP53, PHF6, RUNX1, ETV6, or NPM1 mutations.
§
CBL, NRAS, KIT, JAK2, or MPL mutations.
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